Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521268 | 0.89 | KDM4E (0.32) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL519714 | 0.70 | KDM4E (0.52) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL521646 | 0.70 | JAK2 (0.38) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL521852 | 0.69 | AURKA (0.42) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19876452 | 0.68 | KDM4E (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2IRAK4 | |
| SCHEMBL520503 | 0.68 | INSR (0.42) | KDM4EALDH1A1HPGDSMN1; SMN2KDM4C | |
| SCHEMBL521590 | 0.66 | EGLN2 (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL521339 | 0.66 | FYN (0.41) | — | |
| SCHEMBL520458 | 0.65 | HSP90AA1 (0.42) | — | |
| SCHEMBL519998 | 0.65 | ABCG2 (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | KDM4E 192/4885ALDH1A1 779/4885HPGD 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.